Evidence map›Paper›PMID 40713184›Full record

ArticleSexually transmitted infections2026

Prevalence of chlamydial, gonococcal and syphilis positivity by anatomical site and sex via self-collected biospecimens using at-home testing kits among a large and diverse cohort of men and women enrolled in the MACS/WIHS Combined Cohort Study (MWCCS) in the USA.

Matthew J Mimiaga, Jiahao Tian, Izzy Chiu, Elizabeth A Yonko, Gilda Noori, Najib Aziz, Beth D Jamieson, Yuhang Qian, Maria L Alcaide, Michael Augenbraun and 15 more

Abstract readMulticenter Study
In one paragraph

Article in Sexually transmitted infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Impact of Vaginal Estradiol on the Genitourinary Syndrome of Menopause, Vaginal Microbiome and Mucosal Immune Mediators in Women With HIV.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Trial
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Matthew J MimiagaDepartment of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, CA, USA mmimiaga@ph.ucla.edu.ORCID 0009-0005-9336-5563
Jiahao TianDepartment of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, CA, USA.
Izzy ChiuDepartment of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, CA, USA.
Elizabeth A YonkoDepartment of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, CA, USA.ORCID 0000-0003-4065-1820
Gilda NooriDepartment of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, CA, USA.
Najib AzizDepartment of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, CA, USA.
Beth D JamiesonDepartment of Medicine, Division of Hematology/Oncology, UCLA Geffen School of Medicine, Los Angeles, CA, USA.
Yuhang QianDepartment of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, CA, USA.ORCID 0000-0002-1595-1381
Maria L AlcaideDivision of Infectious Diseases, Miller School of Medicine, University of Miami, Miami, FL, UCLA.
Michael AugenbraunDivision of Infectious Diseases, SUNY Downstate Health Sciences University, Brooklyn, NY, USA.
M Reuel FriedmanDepartment of Urban-Global Public Health, Rutgers, the State University of New Jersey, New Brunswick, NJ, USA.
Mirjam-Colette KempfSchools of Nursing, Medicine and Public Health, University of Alabama at Birmingham, Birmingham, AL, USA.
Jodie Dionne-OdomDivision of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Gypsyamber D'SouzaDepartments of Epidemiology and International Health, Johns Hopkins, Bloomberg School of Public Health, Baltimore, MD, USA.
Andrew EdmondsDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Deborah Konkle-ParkerDepartment of Medicine, Division of Infectious Diseases, The University of Mississippi Medical Center, Jackson, MS, USA.
Audrey L FrenchDepartment of Medicine, University of Illinois Chicago, Chicago, IL, USA.
Ighovwerha OfotokuncDepartment of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA.
Frank J PalellaDivision of Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Michael W PlankeyDepartment of Family Medicine, Division of General Internal Medicine, Georgetown University, Washington, DC, USA.
Anjali SharmaDepartment of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.
Phyllis C TienDepartment of Medicine, Division of Infectious Diseases, UCSF School of Medicine, San Francisco, CA, USA.
Ken HoDepartment of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Adam J ViscontiDepartment of Family Medicine, Division of General Internal Medicine, Georgetown University, Washington, DC, USA.
Roger DetelsDepartment of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, CA, USA.

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Paul A. Goepfert · 1988 to 2026
$84.1M
Engaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
QAQC Johns Hopkins Institute for Clinical and Translational ResearchUL1TR003098 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2019 to 2023
$57.7M
Maternal Morbidity and Mortality: Risk Factors, Early Detection and Personalized InterventionUL1TR001409 · NCATS · GEORGETOWN UNIVERSITY · PI GONDRE-LEWIS, MARJORIE C, MELLMAN, THOMAS A · 2015 to 2024
$37.8M
SF Bay Area MACS/WIHS Combined Cohort StudyU01HL146242 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Bradley E Aouizerat, Jennifer Cohen Price · 2019 to 2026
$36.3M
Sex differences in the role of multi-omicsin HIV-associated carotid artery atherosclerosisU01HL146193 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Stephen J Gange, Elizabeth Topper · 2019 to 2026
$35.8M
University of Miami Developmental Center for AIDS Research (D-CFAR)P30AI073961 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Savita Pahwa · 2007 to 2026
$33.8M
Clinical Research Sites for the MACS/WIHS Combined Cohort Study (MACS/WIHS-CCS) - Baltimore/Wash DC Center - Admin Supplement: Vision and dual sensory loss in HIV-infected older adultsU01HL146201 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI TODD T BROWN, Joseph B. Margolick · 2019 to 2026
$33.7M
Sex differences in the role of multi-omics in HIV-associated carotid artery atherosclerosisU01HL146204 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI David B. Hanna, Anjali Sharma · 2019 to 2026
$33.2M
NCATS NIH HHS KL2 TR001432NCATS NIH HHS TL1 TR001431NCATS NIH HHS UL1 TR000004NCATS NIH HHS UL1 TR001409NCATS NIH HHS UL1 TR001881NCATS NIH HHS UL1 TR003098NHLBI NIH HHS U01 HL146192NHLBI NIH HHS U01 HL146193NHLBI NIH HHS U01 HL146194NHLBI NIH HHS U01 HL146201NHLBI NIH HHS U01 HL146202NHLBI NIH HHS U01 HL146203NHLBI NIH HHS U01 HL146204NHLBI NIH HHS U01 HL146205NHLBI NIH HHS U01 HL146208NHLBI NIH HHS U01 HL146240NHLBI NIH HHS U01 HL146241NHLBI NIH HHS U01 HL146242NHLBI NIH HHS U01 HL146245NHLBI NIH HHS U01 HL146333NIAID NIH HHS P30 AI027767NIAID NIH HHS P30 AI050409NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI073961NIMH NIH HHS P30 MH116867
6 · The paper itself

Abstract

introductionCisgender men who have sex with men (MSM), transgender women, cisgender women and cisgender men who have sex with women only (MSW) have differential risk of acquiring

methodsParticipants are enrolled in the MACS (Multicenter AIDS Cohort Study)/WIHS (Women's Interagency HIV Study) Combined Cohort Study (MWCCS)-the longest-running observational study of both people living with HIV (PLWH) and sociodemographically similar people living without HIV (PLWOH) in the world-with a total of 13 clinical research sites across the USA; participants (N=5700) complete quantitative assessments related to a variety of behavioural and health-related factors every 6 months. Regardless of whether or not they were sexually active or symptomatic/asymptomatic, all enrolled participants (ie, cisgender MSM, transgender women, cisgender women and cisgender MSW) were asked to complete surveillance testing for bacterial STIs (ie, syphilis, CT and GC). In addition to urethral samples, cisgender MSM, transgender women and cisgender MSW collected samples to test for extragenital pharyngeal and rectal CT and GC. Using at-home testing kits, participants self-collected biospecimens (ie, dried blood spots (DBS)/ microtainer of blood, urine and rectal and pharyngeal swabs) which were mailed to a central laboratory for nucleic acid amplification testing (for CT/GC) and syphilis testing using the reverse algorithm. STI results were linked to participants' HIV testing data and self-administered surveys on sociodemographics, sexual behaviours and psychosocial factors.

resultsAmong those tested, 24.6% of cisgender MSM, 25.8% of transgender women, 7.4% of cisgender women and 14.6% cisgender MSW tested positive for at least one STI. Multiple STIs/anatomical sites were detected in 3.9% of participants, with the highest prevalence among transgender women (9.7%). Current/past syphilis prevalence was 11.2% across all participants, with cisgender MSM (19.7%) and transgender women (19.4%) having a higher prevalence than cisgender women (6.4%) and cisgender MSW (12.6%). Regarding CT, 2.1% of the participants tested were positive at one anatomical site. Among those who had extragenital testing, rectal CT was the most prevalent (3.2%), including 3.4% among cisgender MSM, 8.9% among transgender women and 0.9% among cisgender MSW. For GC, 1.4% of participants tested positive at one site. Among those who tested for extragenital STIs, rectal GC was the most common site, with a prevalence of 2.2%, including 2.3% for cisgender MSM, 4.3% for transgender women and 1.4% among MSW. Overall, 7.1% of participants tested positive for CT or GC at one or more anatomical sites. Finally, PLWH had a significantly higher prevalence of syphilis (13.74%) compared with PLWOH (6.11%) (p<0.001).

conclusionThere is a high prevalence of bacterial STIs among participants in the MWCCS. Self-collection of DBS/microtainer of blood, urine and rectal and pharyngeal swabs provided a useful, cost-effective option for screening participants outside of the traditional clinical setting. Given the possible asymptomatic nature of all three STIs, regular testing and education can be key to detection and treatment. Culturally appropriate and locally derived community outreach and engagement can be highly effective in reducing stigma around HIV and STIs and help reduce barriers to testing and treatment.

Indexed as

Chlamydia InfectionsGonorrheaSyphilisAdultChlamydia trachomatisCohort StudiesFemaleHomosexuality, MaleHumansMaleMiddle AgedNeisseria gonorrhoeaePrevalenceSexual and Gender MinoritiesSexual BehaviorSpecimen HandlingChalmydia TrachomatisGonorrheaHIVSexual and Gender MinoritiesSYPHILIS

Identifiers

PMID40713184
PMCPMC12377108

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.